SNDX Earnings & Financial Statements
Syndax Pharmaceuticals, Inc.
$13.47
-$0.06(-0.44%)
37
Overall
40
Value
45
Tech
28
Quality
Market Cap
$1.21B
Volume
913.51K
52W Range
$12.99 - $25.59
Target Price
$37.25
SNDX earnings and financial statements: Syndax Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
SNDX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $172.35M | $23.68M | - | - | $139.71M |
| Cost of revenue | $6.97M | $826.0K | - | - | - |
| Operating income | -$273.08M | -$339.67M | -$229.95M | -$151.76M | $26.22M |
| EBITDA | -$285.19M | -$318.73M | -$209.15M | -$146.17M | $26.87M |
| Net income | -$285.42M | -$318.76M | -$209.36M | -$149.34M | $24.93M |
| EPS (diluted) | $-3.29 | $-3.72 | $-2.98 | $-2.46 | $0.46 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $529.71M | $724.82M | $612.88M | $497.24M | $449.66M |
| Total liabilities | $465.08M | $436.69M | $58.68M | $29.79M | $41.29M |
| Shareholders’ equity | $64.63M | $288.12M | $554.20M | $467.45M | $408.37M |
| Cash and equivalents | $134.93M | $154.08M | $295.39M | $74.36M | $221.97M |
| Long-term debt | - | $333.14M | $578.0K | $709.0K | $20.61M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$322.98M | -$274.90M | -$160.60M | -$133.68M | $29.13M |
| Capital expenditure | -$187.0K | - | - | $225.0K | -$129.0K |
| Free cash flow | -$323.17M | -$274.90M | -$160.60M | -$133.68M | $29.00M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SNDX | $13.47 | -0.4% | 913.51K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Syndax Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW